KDM1A and acute myeloid leukemia: Small-molecule inhibitors of the two families of histone demethylases are at various stages of development, and interest in such compounds has been spurred by emerging preclinical data showing the therapeutic potential of compounds that inhibit LSD1 in acute myeloid leukemia (AML) [39].